[Ip-health] Pharma Anti-Counterfeiting Conference, 30th June-2nd July, London
chan park
chansoobak@gmail.com
Wed Dec 10 03:39:09 2008
Dear Rob, Jamie, and all,
The IMPACT doc discussed below states, "Certain countries have
translated [the WHO definition of counterfeit meds] into their
legislation." Does anyone know which countries have done so?
Thanks in advance.
On Jun 5, 2008, at 7:29 PM, robert weissman wrote:
> This statement does not appear to reflect WHO views. Below is a
> paper on
> estimates that was released by IMPACT, the anti-counterfeiting
> public-private, interagency project spearheaded by WHO. It says the 10
> percent figure is "not supportable." The paper below suggests "it is
> reasonable to estimate that the prevalence of counterfeit medicines
> ranges from less than 1 percent of sales in developed countries, to
> over
> 10 percent in developing countries, depending on the geographical
> area."
>
>
>
> www.who.int/medicines/services/counterfeit/impact/
> TheNewEstimatesCounterfeit.pdf
>
> Counterfeit Medicines: an update on estimates
> 15 November 2006
>
> For the past few years the public opinion and expert circles have
> passively accepted the argument that 10% of medicines around the
> world
> could be counterfeit. This number however, is not supportable,
> because
> this figure fails to reflect the wide range in the proportion of
> counterfeits across countries and because of the difficulties in
> measurement that allow only inferences to be made about the potential
> range of proportion in different regions.
>
> Today, our capacity to collect and analyse available information has
> improved, providing a better understanding of the situation through
> initiatives such as the IMPACT, with input from WHO, OECD, IFPMA, the
> Pharmaceutical Security Institute and others. We feel that an
> effort to
> assess the presence of counterfeiting is fundamental, but also
> that the
> old 10% estimate needs to be clarified.
>
> According to the WHO, a counterfeit medicine is =93a medicine, which is
> deliberately and fraudulently mislabelled with respect to identity
> and/or source. Counterfeiting can apply to both branded and generic
> products and counterfeit products may include products with the
> correct
> ingredients or with the wrong ingredients, without active
> ingredients,
> with insufficient active ingredients or with fake packaging.=94
>
> Certain countries have translated this definition into their
> legislation. The WHO's definition encompasses all the different legal
> definitions we have identified so far. We consider consistent with the
> WHO's definition all national legislation that translates
> =93deliberately
> and fraudulently mislabelled=94 into =93if a product contain less than
> xx%
> of the declared active ingredient is considered counterfeit=94.
>
> We advise against using a single average figure for global
> proportion of
> counterfeit medicines because, besides being necessarily imprecise
> (i.e. not reproducible in subsequent studies) and inaccurate (i.e. not
> reflecting the actual value), a single global ratio blurs the real
> picture and can mislead the public.
>
> Instead, it is necessary to use a range when describing the
> relevance of
> counterfeiting, along with the development status of countries
> affected. Thus, it is reasonable to estimate that the prevalence of
> counterfeit medicines ranges from less than 1 percent of sales in
> developed countries, to over 10 percent in developing countries,
> depending on the geographical area. This range takes into
> consideration
> both regional disparities in the presence of counterfeits, and
> specific
> global market value shares. [1]
>
> -----
>
> Footnote [1]: Global pharmaceutical market shares are 83% for
> developed
> markets, and 17% for developing world. Based on audited IMS sales
> data,
> 2005 publicly available at
> http://www.imshealth.com/ims/portal/front/articleC/
> 0,2777,6599_77478579_77479643,00.html
>
>
> -----
>
> Analysis shows that counterfeiting is greater in those regions where
> regulatory and legal oversight is weaker, and therefore:
>
> - most developed countries with effective regulatory systems and
> market
> control (e.g. USA, EU, Australia, Canada, Japan, New Zealand)
> currently
> have a very low proportion, i.e. less than 1% of market value.
> However,
> we must keep in mind that indications point to an increase in the
> prevalence of counterfeit medicines even in developed countries;
>
> - many developing countries of Africa, parts of Asia, and parts of
> Latin America have areas where more that 30% of the medicines on sale
> can be counterfeit. Other developing markets, however, have less than
> 10%; overall, a reasonable estimate is between 10% and 30%;
>
> - many of the former Soviet republics have a proportion of
> counterfeit
> medicines which is above 20% of market value -this falls into the
> developing country range;
>
> - medicines purchased over the Internet from sites that conceal their
> actual physical address are counterfeit in over 50% of cases.
>
> Apart from the huge differences between regions, variations can
> also be
> dramatic within countries -city versus rural areas, city versus
> city-,
> and can even be time sensitive =96 sometimes counterfeits are openly
> sold
> and sometimes not.
>
> The sources of information, of course, also underlie the complexity of
> any estimation. Detailed data on counterfeit medicines is often
> difficult to obtain or to publish. How to measure a market that, by
> nature, is informal and illegal =96and where evidence is usually
> consumed?
>
> Counterfeiters and their allies know they are committing a crime and
> aggressively seek to avoid detection. They engage in elaborate
> conspiracies to disguise their activities as the masters remain in the
> shadows. They establish fictitious businesses and front companies.
> They
> exploit weaknesses in border control whenever governments try to
> promote world commerce by reducing border inspections. They use false
> documents to obtain essential active pharmaceutical ingredients, as
> well
> as manufacturing equipment to replicate genuine products. In sum,
> their
> actions disguise the extent of crime and makes detection and
> reporting
> extremely difficult.
>
> Currently, the sources of information available include reports from
> national authorities, such as drug regulatory and enforcement
> agencies,
> ad hoc studies conducted on a specific geographical area or
> therapeutic
> category, reports from the pharmaceutical sector, reports from NGOs
> and
> surveys.
>
> In summary, the estimated range does not aim at providing an exact
> figure but rather an indication of the different possible levels of
> prevalence around the world. Even one single case of counterfeit
> medicine is not acceptable because, in addition to putting
> patients at
> risk and undermining the public confidence in their medicines, it
> also
> betrays the vulnerability of the pharmaceutical supply system and
> jeopardizes the credibility of national authorities (health and
> enforcement alike).
>
> Annex
>
> 2006 Reports
>
> Russia: The Federal Service for Health Sphere Supervision (FSHSS)
> reported that 10% of all drugs on the Russian market were
> counterfeit.
> However, other sources estimate that the real figure could be much
> higher.
>
> Nigeria: The National Agency for Food, Drug Administration and Control
> (NAFDAC) announced that the prevalence of counterfeit drugs has
> dropped
> to 16% at the beginning of 2006.
>
> Reports Before 2006
>
> Dominican Republic: The Public Health Department reported that 50% of
> the pharmacies operate illegally and that, according to the
> statistics,
> 10% of the medicines that arrive in the country are fake. Some of the
> medicines found have expired over 10 years ago.
>
> El Salvador: INQUIFAR, the association of pharmaceutical companies
> in El
> Salvador, has denounced the widespread availability of counterfeit
> drugs on the domestic market. According to the local drug-maker Gamma
> Laboratorios, the commercialization of counterfeit medicines currently
> generates economic losses of around $40 million per year to the
> country's pharmaceutical industry.
>
> Indonesia: The International Pharmaceutical Manufacturers Group (IPMG)
> in Indonesia has estimated that pirated drugs constitute 25% of
> Indonesia=92s $2 billion pharmaceutical market. According to IPMG=92s vic=
e
> chairman, those fake drugs hit foreign pharmaceutical companies=92
> bottom
> lines and pose a potential serious public health threat.
>
> Kenya: A random survey by the National Quality Control Laboratories
> (NQCL) and the Pharmacy and Poisons Board found the almost 30% of
> drugs
> in Kenya are counterfeit. According to Dr. Hezekiah Chepkwony of the
> NQCL, "Some of the drugs are no more than just chalk or water being
> marketed as competent pharmaceutical products." According to figures
> from the Kenyan Association of Pharmaceutical Industry, counterfeit
> pharmaceutical products account for approximately $130 million
> annually
> in sales in the country.
>
> Peru: Some $66 million of counterfeit and adulterated pharmaceuticals
> are sold in Peru every year. In Lima alone there are 1,800 stores
> devoted to this illegal business. The General Directorate of
> Medicines,
> Supplies and Drugs (DIGEMID) of the Department of Health (MINSA)
> seized around 460,000 adulterated and expired medicines in 2005.
>
> Angola: According to the head of the National Department of
> Intellectual
> Copyright Crime of the Economic Police, Apolinario Antonio Domingos,
> approximately 70% of medicines used by the Angolan population are
> forgeries.
>
> Colombia: According to Alberto Brave, Executive President of the
> Association of Colombian Pharmaceutical Industries (ASINFAR), it has
> been estimated that of a total of an annual $1,300 million sold in
> medicines, near 5 percent (some $60 million), of the products marketed
> stem from contraband, counterfeiting or adulteration.
>
> Lebanon: The chief of Lebanon=92s National Health Commission (NHC),
> Ismail
> Sakaria, stated in July 2004 that 35% of pharmaceuticals available in
> the Lebanese market are counterfeit products.
>
> exico: During 2004, federal agents seized in Sahuayo, Michoac=E1n,
> and in
> Guadalajara, Jalisco, approximately 60 tons of stolen, expired and
> counterfeit pharmaceuticals. There is concern in the pharmaceutical
> industry because of the growth in sales of counterfeit and contraband
> products. Reportedly, the penetration of these illegal products is
> about 10% of the pharmaceutical market.
>
> Nigeria: The chairman of Ebonyi State Task Force on Counterfeit and
> Fake
> Drugs, Emmanuel Inya-Agha stated that approximately 48% of goods and
> drugs imported into the country are substandard or counterfeit.
> Peru: Around 200 pharmacies operate in downtown Lima with neither
> registration nor authorization issued by the ministry of health.
> According to Mr. Javier Llamoza from the municipal health department,
> they sell 40% contraband pharmaceuticals and 12% adulterated or
> expired
> supplied by clandestine laboratories. During 2004, the ministry of
> health seized ten tons of adulterated pharmaceuticals.
>
> Philippines: The former director of the Bureau of Food and Drug
> (BFAD),
> William Torres, was quoted in newspapers saying, "that 30% of drug
> store outlets visited by food and drug deregulation officers carry
> and
> sell counterfeit drugs, as of 2003."
>
> Cambodia: A Cambodian Health Ministry survey conducted in 2002
> revealed
> that 13% of drugs on the domestic market were counterfeit or
> substandard, especially the anti-malaria drugs and antibiotics.
>
> China: China=92s Research and Development-based Pharmaceutical
> Association
> estimated that about 8% of over-the-counter drugs sold in China are
> counterfeit.
>
> India: Indian pharmaceutical companies have suggested that in India=92s
> major cities, one in five strips of medicines sold is a fake. They
> claim a loss in revenue of between 4% and 5% annually. The industry
> also
> estimates that spurious drugs have grown from 10% to 20% of the total
> market.
>
> Nigeria: Nigerian health officials estimate that 70% of drugs in
> circulation in the country are either fake or adulterated.
>
> Peru: The Association of Pharmaceutical Laboratories of Peru
> (ALAFARPE)
> estimates that the illegal pharmaceuticals commerce in the country
> represents around $40 million. This figure includes medicines that
> enter the country as contraband, expired, counterfeit, adulterated,
> with
> altered or missing labels and those stolen from the warehouses of the
> Ministry of Health, the armed forces, and police.
>
>
> James Love wrote:
>> Does anyone know who at the WHO has made this claim?
>>
>> * "The WHO estimates that 10% of global pharmaceutical commerce
>> involves
>> counterfeits."
>>
>>
>> -------- Forwarded Message --------
>> From: Jacob Samek - Visiongain Ltd.
>> <pharma.conferences1@conferencesandreports.com>
>> Reply-To: pharma.conferences1@conferencesandreports.com
>> To: james.love@cptech.org
>> Subject: Pharma Anti-Counterfeiting Conference, 30th June-2nd July,
>> London
>> Date: Thu, 5 Jun 2008 04:41:37 +0100
>>
>> =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D
>> Pharmaceutical Anti-Counterfeiting Strategies Forum 2008
>> =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D
>> 30th June, 1st & 2nd July 2008, BSG House, London
>>
>> Worldwide sales of counterfeit drugs could nearly double to $75bn
>> (=8060bn, =A340bn) by 2010, according to the Center for Medicine in the
>> Public Interest. In some developing countries more than 50 per
>> cent of
>> the drug supply is said to be counterfeit. There needs to be greater
>> discussion within the industry about how to fight this problem.
>> That is
>> why the industry has made the decision to come together, meet and
>> discuss how to tackle this dangerous issue as a united body.
>>
>> RFID, bar coding, holograms, and colour-shifting inks are very well
>> known as methods of combating pharmaceutical counterfeiting. But the
>> industry is constantly in search of innovative strategies to stay
>> ahead
>> of the fraudsters. Where the industry hears about the latest
>> techniques
>> and strategies is at the Annual Pharmaceutical Anti-Counterfeiting
>> Strategies Conference. Will you be attending next year? If you
>> want to
>> hear about some of the latest strategies such as transparent laser
>> markings of encrypted code on single product items, or new finger
>> print
>> technologies, or the latest in surface authentication systems, then
>> really you need to be there.
>>
>> The last five years have seen an explosive growth in counterfeit
>> prescription drugs that is showing no signs of relenting. This has a
>> serious impact on your profit margins and poses a direct threat by
>> putting patient=92s lives at risk. The WHO estimates that 10% of global
>> pharmaceutical commerce involves counterfeits. International crime
>> syndicates are becoming more sophisticated and better organised in
>> counterfeiting. Is this problem at risk of spiralling out of control?
>> Many analysts believe so with counterfeiting expected to reach 20 per
>> cent by the 2010. They believe that as a result, counterfeiting will
>> jeopardize fundamental trust in the pharmaceutical industry. So
>> why is
>> the industry waiting for a catastrophic failure before confronting
>> inherent weaknesses in the system? Many aren't and the first step
>> they
>> are taking is to meet and discuss how the industry can fight back.
>> And
>> where they are meeting is in London from the 24th - 26th January. You
>> must attend.
>>
>> The Annual Anti-counterfeiting Strategies Forum will enable global
>> regulatory bodies, pharmaceutical, security and anti-counterfeiting
>> companies to come together to discuss and plan a regulatory
>> commercial
>> strategy to tackle this critical problem. So how will the industry
>> seek
>> to identify the most effective countermeasures to manage risk,
>> minimize
>> brand erosion and loss of sales? Book your place now so that you
>> can put
>> you and your company=92s voice forward in this Annual Forum.
>>
>> The international conference will cover themes of:
>> - Routes to enabling cross-border co-operation with international
>> security organisations
>> - Implementation of the latest tamper-proof and automatic drug recall
>> technology
>> - Enhancing supply chain security through new configurations in
>> existing
>> technology
>> - Ancillary benefits of improved systems for inventory and
>> distribution
>>
>>
>> Speakers include:
>> * Andrew Jackson, Deputy Global Head, Corporate Security, Novartis
>> * Janice Kite, Project Manager Traceability in Healthcare, GS1
>> * Andrew Jenner, Head of IP Crime Policy, UK Intellectual Property
>> Office
>> * Christopher Stothers, Associate, Intellectual Property Practice
>> Group,
>> Millbank, Tweed, Hadley and McCloy
>> * Monika Derecque-Pois, Secretary General, GIRP
>> * Eric Noehrenberg, Director, International Trade & Market Policy,
>> International Federation of Pharmaceutical Manufacturers Associations
>> * Jim Thomson, CEO, Centre for Mental Health
>> * Christine H=E4nle, Corporate Purchasing Ethical Manager, Celesio
>> * Leam Thompson, In house Counsel, Asset Investigation &
>> Confiscation,
>> BDO Stoy Hayward
>> * Heinz Kobelt, Secretary General, European Association
>> Euro-Pharmaceutical Companies
>>
>>
>> Key benefits of attending
>> - Identifying the scale of the problem and the drugs most commonly
>> counterfeited
>> - Discover the legal issues surrounding counterfeit drugs
>> - Gaining insight to the market effects of parallel trading and
>> ways to
>> regulate it
>> - Enhancing detection methods of fake products and ultimately deter
>> counterfeiting
>> - Minimizing the harm to brand name from market recall incidents
>>
>> How will you benefit from attending this event?
>> * Meet your peers to discuss and shape the future strategies the
>> industry plans to take
>> * Network with senior representatives from Global regulatory
>> bodies as
>> well as major pharmaceutical companies and hear how they plan to
>> tackle
>> the industry wide problem
>> * Gain an up-to-date overview and understanding of the most vital
>> concerns in the battle against counterfeiters
>> * Learn how to achieve a competitive edge and mitigate risks
>> through an
>> active approach with procedures to safeguard against counterfeiting
>> * Explore partnership opportunities between technology providers and
>> pharmaceutical corporations to enhance security of the supply chain
>>
>> If you only attend one event this year make sure it is the conference
>> that will guarantee your success for the next few years. Places at
>> this
>> conference are limited and are issued on a strict first come, first
>> served basis. Contact me now to reserve your seat.
>>
>>
>> _____________________________________________________________________
>> ___
>>
>> Sponsorship and exhibition opportunities:
>>
>> If you would like benefit by promoting your organisation at one of
>> our
>> events then exhibiting is perfect for you.
>> - Network with industry decision-makers
>> - Increase and maintain brand awareness
>> - Meet potential clients face to face
>> - Target your marketing campaign
>> - Present your latest products and ideas
>>
>> Places at this global forum are by invitation only. The Annual
>> Pharmaceutical Anti-counterfeiting Strategies Forum is growing
>> each year
>> as members of the industry meet and benefit from the forum of open
>> discussion and networking. It is by tackling the problem together
>> that
>> we hope to combat and rid the industry of the dangers of counterfeit
>> drugs. I would like to extend this invitation to attend to you and
>> would
>> request that you contact us now to register your attendance. We
>> can then
>> dispatch your booking confirmation and letter of approval.
>>
>> _____________________________________________________________________
>> ___
>> Who should attend:
>> - Pharmaceutical companies
>> - Pharmaceutical distributors
>> - Government health departments
>> - Public health and regulatory bodies
>> - Law enforcers =96 police, customs agencies, investigative firms
>> - Non-government healthcare organisations
>> - Pharmaceutical associations
>> - Converters, packaging and labelling companies
>> - Authentication technology suppliers
>>
>> Job titles: Directors, Heads and Managers of:
>> - Supply Chain and Distribution
>> - Packaging and Labeling
>> - Compliance
>> - Security
>> - Information Systems
>> - Regulatory Affairs
>> - R&D
>> - Business Development and Marketing
>> - Product Information
>> - Standards
>> - Patient Safety
>> - Pharmaceuticals/Life Sciences Analyst or
>> - Business Development
>> - Marketing
>> - Sales
>> - Security managers
>>
>> _____________________________________________________________________
>> ___
>> Conference Agenda
>>
>> Pre Conference Workshop, 30th June, Monday
>>
>> Recent Trends in International Counterfeiting
>>
>>
>> Will include topics such as:
>> =95 Transit shipments after Diesel v Montex
>> =95 Liability of carriers/freight forwarders
>>
>>
>> Daniel Marschollek, Partner, Mayer Brown
>>
>>
>> Day One, 1st July, Tuesday
>> 08:30 Refreshments and registration
>>
>> 09:30 Registration and refreshments
>>
>> 10:00 Opening address from the chair
>> - Eric Noehrenberg, Director, International Trade & Market Policy,
>> International Federation of Pharmaceutical Manufacturers Associations
>>
>> 10:10 A global strategy to fight counterfeiting
>> =95 A safe and secure supply chain
>> =95 Authentication and traceability
>> =95 Activities of regulatory bodies and industry worldwide
>> =95 Global standards =96 how do they help fighting counterfeiting?
>>
>> Janice Kite, Project Manager Traceability in Healthcare, GS1
>>
>> 10:50 Technological and non-technological measures
>> - How can we protect patients?
>> =95 Product coding and identifications as pre-requisite for tracking
>> and
>> tracing
>> =95 Bar codes versus RFID
>> =95 EU versus US: are the approaches different?
>> =95 Stake holder and government initiatives
>>
>> - Monika Dereque-Pois, Director General, GIRP
>>
>> 11:30 Morning refreshments
>>
>> 11:50 The costs of counterfeit drugs
>> =95 The burden on the health care system
>> =95 Financial damage due to loss of sales and a reduced return on R&D
>> investments
>> =95 The cost of a damaged brand
>>
>> - Paul Forster-Jones, Managing Director, Cordia Healthcare, Board
>> Member, UniChem
>>
>> 12:30 Stake holder and government initiatives combating
>> counterfeits of
>> medicinal products
>> =95 The size of the problem
>> =95 The technological approach
>> =95 The logistical approach
>> =95 Global asset tracing: identification of conduct & property
>>
>> - Tassilo Korab, Executive Director, Health Compliance Packaging
>> Council
>>
>> 13:10 Networking lunch
>>
>> 14:30 The changes in European policy
>> =95 Protecting IP rights
>> =95 Is the European Union finally combating counterfeiters?
>> =95 What will be the end result?
>>
>> 15:10 The UK national IP crime strategy
>> =95 The difference between industry sectors and IP crime
>> =95 How pursing IP infringements can deter pharmaceutical
>> counterfeiting
>>
>> - Andrew Jenner, Head of IP Crime Policy, UK Intellectual Property
>> Office
>>
>> 15:50 Afternoon refreshments
>>
>> 16:10 Closing the Security Loop: Extending E-Pedigree From Package to
>> Patient
>> =95 Counterfeiting of medications continues to escalate and is
>> estimated
>> to
>> reach $75 billion by 2010
>> =95 Most Brand Protection and E-Pedigree solutions focus on ON-Package
>> solutions such as RFID and 2-D bar coding
>> =95 On-Package solutions are deemed effective but are lost once
>> product is
>> repackaged or if the product is separated from its original
>> packaging, a
>> common occurrence in today=92s world
>> =95 To close the loop on product security, On-Dosage technologies that
>> complement
>> On-Package solutions should be employed to extend protection to the
>> patient
>> =95 Combined with a pro-active product sampling program at the retail
>> level, On-
>> Dosage technologies can provide an =93Early Warning=94 system for
>> counterfeits
>> and illegal diversion, allowing Pharmaceutical Manufacturers to
>> strike
>> back at
>> those who steal their profits at the expense of patient=92s well-
>> being and
>> safety
>>
>> - Dean Hart, Executive Vice President Comersial Operations, Nanoink
>>
>> 16:30 Panel discussion: Fighting the fakes =96 To choose a combat
>> strategy
>> =95 Should we focus on technology, legislation or a logistic approach?
>> =95 Will tracking and tracing keep the supply chain safe?
>> =95 Are the various efforts to combat counterfeiters coordinated
>> enough?
>>
>> 17:10 Closing remarks from the chair
>>
>> 17:15 Networking drinks
>> Take your discussions further and build new relationships in a
>> relaxed
>> and informal setting
>>
>> Day Two, 2nd July, Wednesday
>> 09:30 Registration and refreshments
>>
>> 10:00 Opening address from the chair
>>
>> Eric Noehrenberg, Director, International Trade & Market Policy,
>> International Federation of Pharmaceutical Manufacturers Associations
>>
>> 10:10 Defending brands & pursuing offenders: The identification,
>> pursuit, management & recovery of the proceeds of counterfeiting
>> =95 Deterrents & disruption
>> =95 Exploration of existing legislative provision to recover the
>> proceeds
>> of counterfeiting
>> =95 Alternative civil remedies
>> =95 Global asset tracing: identification of conduct & property
>>
>> - Leam Thompson, In house Counsel, Asset Investigation &
>> Confiscation,
>> BDO Stoy Hayward
>>
>> 10:50 Presentation to be announced
>>
>> - Cindy M=FCller, President, Bilcare Europe
>>
>> 11:30 Morning refreshments
>>
>> 11:50 Anti-Counterfeiting technologies in the pharmaceutical
>> industry =96
>> How to be effective
>> =95 Understanding the pharmaceutical protection requirements
>> =95 The multi-layer approach
>> =95 Technologies, applications and success stories
>> =95 Tracing, e-pedigree and online-authentication
>> =95 Pre-requisites of a successful brand protection campaign
>>
>> - Thomas Voelcker, Director Marketing and Sales, Schreiner ProSecure
>>
>> 12:30 Supply chain security =96 the logistic view
>> =95 Are anti-counterfeiting strategies interfering with the
>> logistics of
>> the
>> supply chain?
>> =95 Examining the impact of different strategies on the supply chain
>> =95 Technology and logistics =96 how can you use anti-counterfeiting
>> to aid
>> logistics
>>
>> - Mark Harvey, Head of Security, NYK Logistics
>>
>> 13:10 Networking lunch
>>
>> 14:30 Counterfeit drugs on the internet
>> =95 The relevance of consumer education as a part of the strategy to
>> fight
>> counterfeit drugs
>> =95 Advertising on the internet
>> =95 Monitor internet pharmacies arranging supply chains against
>> counterfeits and diversion through on-line purchases
>>
>> - Andrew Jackson, Deputy Global Head, Corporate Security, Novartis
>>
>> 15:10 The reality of internet pharmacies
>> =95 Presenting a study of the quality of drugs bought of the internet
>> =95 Buying medicine over the internet; where does the money go?
>>
>> - Jim Thomson, CEO, Centre for Mental Health
>>
>> 15:50 Afternoon refreshments
>>
>> 16:10 Parallel trade and counterfeit pharmaceuticals
>> =95 The current framework for parallel trade and repackaging of
>> pharmaceuticals
>> =95 Discovery of counterfeit pharmaceuticals in the parallel supply
>> chain
>> =95 Actual and proposed changes to the distribution and parallel trade
>> framework
>>
>> - Christopher Stothers, Associate, Intellectual Property Practice
>> Group,
>> Milbank, Tweed, Hadley and McCloy
>>
>> 16:50 The contribution of parallel trade distribution to a safe
>> supply
>> chain
>> =95 While legal in the EU/EEA area, PT is often perceived by
>> manufacturers
>> (although not by regulators) as a weakening of the distribution chain
>> =95 The EAEPC argues that its members provide identical medicines at
>> lower
>> cost than manufacturers=92 prices to patients and final payers. Members
>> share with manufacturers the objective of fighting against
>> counterfeits
>> and raising the barriers to keep these out of the legitimate supply
>> chain
>> =95 This presentation looks at the regulatory environment for parallel
>> distribution and looks at the rigorously controlled business
>> practices
>> of re-packaging/re-labelling, and will demonstrate the safety
>> profile of
>> the industry. The presentation will address ways to improve the
>> supply
>> chain without jeopardizing the freedom of movement of pharmaceutical
>> goods across Europe.
>>
>> - Heinz Kobelt, Secretary General, European Association
>> Euro-Pharmaceutical Companies
>>
>> 17:30 Chair=92s closing remarks
>>
>> _____________________________________________________________________
>> ___
>> List of upcoming events
>>
>> You may be also interested in attending other events Visiongain
>> organises. Below you can find list of these events.
>> If you would like to receive more information, do not hesitate
>> contacting me.
>>
>> 3rd Annual Pharmacovigilance
>> 11th - 13th June 2008, London, UK
>>
>> Dissolution Testing, Bioequivalence and Bioavailability Strategies
>> 26th - 27th June 2008, London, UK
>>
>> In Vitro-in Vivo Correlation (IVIVC) Training Course
>> 22nd July, London, UK
>>
>> Lyophilisation for Pharmaceuticals 2008
>> 3rd - 5th September, London, UK
>>
>> 2nd Annual Optimising Stability Testing
>> 17th - 19th September, London, UK
>>
>> Obesity Drug Development Colloquium
>> 24th - 26th September 2008, London, UK
>>
>>
>> _____________________________________________________________________
>> ___
>>
>> - PRICING -
>> - 3 day Conference ticket (inc. pre-conference workshop) -
>> available for
>> only GBP =A3999 (NORMAL PRICE =A31699)
>> - 2 day Conference ticket - available for only GBP =A3799 (NORMAL PRICE
>> =A31299)
>> - Pre-conference workshop only - GBP =A3599
>>
>> If you would like to send more than 1 person then take advantage
>> of the
>> 3 for 2 offer. Send 3 people but only pay for 2
>>
>> Excellent networking opportunities.
>>
>> - ORDERING -
>> Ordering is simple! All you need to book your place is contact Jacob
>> today. You can either email me at
>> pharma.conferences1@conferencesandreports.comor call on TEL: +44
>> (0)207
>> 549 9971.
>>
>> Kind regards,
>>
>> Jacob Samek
>> Visiongain Ltd.
>> 4th Floor,
>> BSG House,
>> 226-236 City Road,
>> London
>> EC1V 2QY
>> United Kingdom
>>
>>
>> _____________________________________________________________________
>> ___
>>
>>
>>
>> _______________________________________________
>> Ip-health mailing list
>> Ip-health@lists.essential.org
>> http://lists.essential.org/mailman/listinfo/ip-health
>>
>
> _______________________________________________
> Ip-health mailing list
> Ip-health@lists.essential.org
> http://lists.essential.org/mailman/listinfo/ip-health